ISTA Pharmaceuticals releases preliminary results from phase II/III study of bepotastine

ISTA Pharmaceuticals Inc. announced results from the preliminary analysis of its phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily.

Related Videos
View All
Related Content

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Orbis announces 3-year partnership with HOYA Vision Care

February 2nd 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

ML6710i photodynamic laser for use with VISUDYNE approved by the FDA

February 1st 2023

Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

February 1st 2023

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Orbis announces 3-year partnership with HOYA Vision Care

February 2nd 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

ML6710i photodynamic laser for use with VISUDYNE approved by the FDA

February 1st 2023

Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

February 1st 2023

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Orbis announces 3-year partnership with HOYA Vision Care

February 2nd 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

ML6710i photodynamic laser for use with VISUDYNE approved by the FDA

February 1st 2023

Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

February 1st 2023
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.